A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Stopped early · Phase 2

Conditions studied: Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer

In brief

A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Key facts

Study ID
NCT04363801
Run by
Leap Therapeutics, Inc.
People needed
247
Starts
2020-07-29
Expected to finish
2025-03-31
Last updated by the study team
2025-10-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.